Table 2.

Percent of patients prescribed voriconazole (VCZ) per the CYP2C19-guided prophylaxis protocol

Patients CYP2C19 genotyped receiving/not receiving VCZ (n=263)	No. (%)
Did not receive VCZ	44 (16.7)
Received VCZ	219 (83.3)
Reason for VCZ prescribing (n=219)	No. (%)
Treatment	17 (7.8)
Prophylaxis	202 (92.2)
Followed CYP2C19-guided prophylaxis protocol	No. (%)
All genotype groups (n=202)	176 (87.1)
CYP2C19*1/*17 group (n=58)	46 (79.3)
CYP2C19*17/*17 group (n=5)	4 (80)
Reason for not following the protocol	No. (%)
Weight‒obese dosing	1 (3.9)
Prior VCZ pharmacokinetics	1 (3.9)
Patient died before CYP2C19 returned	1 (3.9)
Elevated liver enzymes	3 (11.5)
Unknown	6 (23.1)
Patient discharged from hospital before CYP2C19 returned	14 (53.8)